openPR Logo
Press release

myriamed is now a member of Ksilink

10-26-2020 09:09 AM CET | Health & Medicine

Press release from: myriamed GmbH

myriamed is now a member of Ksilink

myriamed is now a member of Ksilink

We proudly announce that myriamed GmbH is now a member of the Ksilink association. The public private association is aiming to render drug development faster and more efficient, heading towards precision medicine. Together with its partners Ksilink develops and applies patient based disease models for phenotypic drug discovery purposes, and generates novel molecular entities for diseases with a high medical need, such as cardiac disorders. Ksilink is covering the entire preclinical value chain by combining break-through technologies and know-how in patient-based disease modelling, AI based image analysis methodologies, phenotypic drug discovery, pharmacology and medicinal chemistry. This strategic partnership is a key step in myriamed’s efforts to support pharmaceutical companies in the discovery and preclinical testing of novel drug candidates.

Since 2018 myriamed is already involved in a collaboration project with Ksilink, exploiting human induced pluripotent stem cell (iPSC) derived models of dilated cardiomyopathy (DCM). The project is based on analyzing relevant model systems that reproduce morphometric and functional hallmarks of DCM in vitro. The complexity of DCM pathophysiology and the selectivity of morphological and functional abnormalities in cardiomyocytes can be recapitulated in cellular disease model systems derived from differentiated iPSC cultures. These model systems will be used in a high throughput, high content screen, analyzing multiple phenotypic parameters such as the subcellular distribution of sarcomeric proteins by applying latest deep learning methodologies.

About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in the controlling of their fate as to the differentiation into defined cellular lineages and tissues (published for example in Tiburcy et al. 2017 and Long et al. 2018). The myriamed product portfolio is constantly evolving and based on a comprehensive IP portfolio to offer its know-how and associated services in drug development.
myriamed gives access to the following expertise:

• high quality human iPSC-derived somatic cells (myrCell) to be used in drug discovery and development.

• macroscale (3D) tissue (myrTissue) generated from the respective iPSC lines with properties of postnatal tissue for advanced screening and target validation.

• A highly parallelized phenotypic screening service (myrScreen).

myriamed has therefore two main types of activities, the generation of high-quality biological material allowing the research of new therapeutic targets, and the realization of customized phenotypic screenings.

To learn more about myriamed’s products please contact us:

About Ksilink: Ksilink is a private-public translational association aiming in phenotypic patient-based drug discovery and preclinical development of novel molecular entities. Ksilink was founded in 2014 in the heart of Europe in Strasbourg, France with the objective to establish a unique end-to-end translational concept with compiled expertise from academia and industry managing high-end equipped platforms for disease modeling, large scale cell production, AI driven image analysis, phenotypic screening, pharmacology and medicinal chemistry. Together with its 12 industrial and academic members and a dedicated platform, Ksilink bridges the gap between the scientific excellence of German and French R&D and the pharmaceutical industry by generating tangible results for the benefit of patients. Members of the Ksilink association are the national institute for health and medical research INSERM, the University of Heidelberg and the University of Strasbourg, the Central Institute for Mental Health CIMH, the German Cancer Research Center DKFZ, the patient organization AFM Téléthon the German Lead Discovery Center LDC, the two biotech companies Life&Brain and myriamed GmbH, the healthcare industry clusters BioPro Baden Württemberg GmbH and BioValley France, and Sanofi.
To learn more about Ksilink please visit:

myriamed GmbH
Rudolf-Wissell-Str. 28a
37079 Göttingen
Tel.: +49 551 28878-170

myriamed – the drug development accelerator

Separating the pharmacological wheat from the chaff is the primary goal of myriamed. Our proprietary human cell and engineered tissue models allow for the simulation of health and disease in the dish. Our platform technologies find broad applications in early stages of drug discovery and refinement of the most promising therapeutic candidates.
The availability of human cell and tissue models is transforming preclinical drug development. Applications range from early stages of lead discovery to advanced individualized phenotypic screens to shape a promising therapeutic candidate. myriamed offers a broad portfolio of highly standardized services as well as custom-made solutions to accelerate drug development.
At myriamed we focus on heart and skeletal muscle as well as on neuronal organoids. Our myrCell and myrTissue platforms define wanted and unwanted drug effects in a unique human context. myrScreen combines our expertise in phenotypic drug screens and enables deep phenotyping of drug effects on healthy or diseased human heart and skeletal muscle as well as on neuronal organoids.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release myriamed is now a member of Ksilink here

News-ID: 2171135 • Views: 498

More Releases from myriamed GmbH

myriamed has joined Science Exchange
Science Exchange, the leading SaaS-enabled marketplace platform for outsourced R&D services, has partnered with myriamed. Visit myriamed’s profile to inquire about our services or request a quote. There are no additional contracts required if you request on Science Exchange and you can order immediately. Please visit our profile here: About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and
myriamed is now a member of the Network for Pharma Solutions
We are proud to announce that myriamed is now a member of the Network for Pharma Solutions (NetPhaSol). NetPhaSol is a cooperation network focusing on drug discovery & development. It serves as a platform for research, development and marketing of new products, technologies and services in drug development. About myriamed: myriamed has unique expertise in research and development of human induced pluripotent stem cells (iPSC), including genome edited lines, and in
Helping to accelerate the development of novel drugs against Covid-19 disease
Even though vaccines against Covid-19 will be available soon, artificial herd immunity via vaccination will probably not reached until the end of 2021. Thus, the current fight against Covid-19 disease heavily relies on already available drugs. Unfortunately, there is hardly any drug that fights the disease effectively. Cortisone based therapeutics are currently the ones used most frequently and most successfully. The originally promising drug Remdesivir, which has been approved for the
myriamed’s myrPlates are now also available from ZAGENO
We are proud to announce that myriamed’s myrPlates are now also available in the ZAGENO life science, e-commerce marketplace. myrPlates can be used for the generation of engineered human tissues. By parallel culture of up to 48 tissues in one myrPlate, e.g. contractile heart muscles or skeletal muscles can be obtained to serve numerous applications, such as drug screening and disease modelling. About myriamed: myriamed has unique expertise in research and development

All 5 Releases